Track the INCYTE CORPORATION stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €26bn. The latest transaction was reported on 19 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: PABLO CAGNONI. The full history is openly available.
11
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate INCYTE CORPORATION Buy (bullish), based on 23 analysts. Average price target: US$125.17.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,627 of 28,900 companies
74.7
score / 100
Value
56
Quality
94
FCF yld5.1%
Earn yld4.9%
EV/EBITDA15.0x
ROE31%
Gross mgn93%
Net mgn25%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,639 shares@ US$100.00100.0% of flowCommonSEC144:0001950047-26-005611
11 of 11 declarations
About INCYTE CORPORATION
INCYTE CORPORATION is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and immune-related diseases. It is listed on NASDAQ under the ticker INCY.